RANI logo

RANI
Rani Therapeutics Holdings Inc - Ordinary Shares Class A

2,122
Mkt Cap
$116.36M
Volume
620,258.00
52W High
$3.87
52W Low
$0.387
PE Ratio
-1.60
RANI Fundamentals
Price
$0.94
Prev Close
$0.8879
Open
$0.9106
50D MA
$1.07
Beta
1.62
Avg. Volume
903,189.52
EPS (Annual)
-$0.4486
P/B
2.78
Rev/Employee
$23,000.00
$52.20
Loading...
Loading...
News
all
press releases
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the company...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Rani Therapeutics (NASDAQ:RANI) Earns Buy Rating from Analysts at Lake Street Capital
Lake Street Capital initiated coverage on Rani Therapeutics in a research report on Tuesday. They set a "buy" rating and a $9.00 price target on the stock...
MarketBeat·18d ago
News Placeholder
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the company...
MarketBeat·1mo ago
News Placeholder
Canaccord Genuity Group Lowers Rani Therapeutics (NASDAQ:RANI) Price Target to $5.00
Canaccord Genuity Group lowered their target price on Rani Therapeutics from $9.00 to $5.00 and set a "buy" rating for the company in a report on Wednesday...
MarketBeat·1mo ago
News Placeholder
Equities Analysts Offer Predictions for RANI Q1 Earnings
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Rani Therapeutics in a report issued on Friday, March...
MarketBeat·1mo ago
News Placeholder
Rani Therapeutics (NASDAQ:RANI) Given "Buy" Rating at HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Rani Therapeutics in a research report on Friday...
MarketBeat·1mo ago
News Placeholder
Rani Therapeutics Q4 Earnings Call Highlights
Rani Therapeutics (NASDAQ:RANI) executives highlighted what they described as a transformational 2025 during the company's fourth-quarter and full-year earnings call, pointing to progress advancing...
MarketBeat·1mo ago
News Placeholder
Rani Therapeutics (NASDAQ:RANI) Announces Quarterly Earnings Results
Rani Therapeutics (NASDAQ:RANI - Get Free Report) posted its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The...
MarketBeat·1mo ago
News Placeholder
Rani Therapeutics (RANI) Expected to Announce Earnings on Monday
Rani Therapeutics (NASDAQ:RANI) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-rani-therapeutics-holdings-inc-stock...
MarketBeat·1mo ago
News Placeholder
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of "Moderate Buy" from Brokerages
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five analysts that are presently covering the stock, MarketBeat...
MarketBeat·2mo ago
<
1
2
...
>

Latest RANI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.